Published in Arch Intern Med on January 24, 2005
Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer (2006) 1.71
Coxibs, science, and the public trust. Arch Intern Med (2005) 1.43
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol (2006) 1.13
Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships. Br J Clin Pharmacol (2006) 0.93
Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther (2007) 0.92
Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther (2005) 0.89
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther Clin Risk Manag (2007) 0.87
An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol (2007) 0.81
Myocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis. Perm J (2008) 0.79
Depression following thrombotic cardiovascular events in elderly medicare beneficiaries: risk of morbidity and mortality. Cardiol Res Pract (2009) 0.75
MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health (2007) 3.05
Patterns and correlates of linkage to appropriate HIV care after HIV diagnosis in the US Medicaid population. Sex Transm Dis (2013) 2.92
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol (2012) 2.82
Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation (2010) 2.76
The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med (2009) 2.76
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. Am Heart J (2008) 2.61
Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol (2005) 2.47
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med (2003) 2.45
Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2012) 2.42
Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Spec Pharm (2014) 2.03
Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. Arthritis Rheum (2008) 1.97
Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol (2002) 1.97
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol (2008) 1.91
The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant (2001) 1.88
Burden of concomitant asthma and COPD in a Medicaid population. Chest (2008) 1.87
Cost-of-illness studies : a review of current methods. Pharmacoeconomics (2006) 1.84
Patients' attitudes about living donor transplantation and living donor nephrectomy. Am J Kidney Dis (2003) 1.80
Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care (2010) 1.75
A study of renal outcomes in obese living kidney donors. Transplantation (2010) 1.67
Genotype-based changes in serum uric acid affect blood pressure. Kidney Int (2011) 1.62
Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int (2011) 1.61
Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens (2009) 1.57
Have we fallen off target with concerns surrounding dual RAAS blockade? Kidney Int (2010) 1.55
A prospective controlled study of kidney donors: baseline and 6-month follow-up. Am J Kidney Dis (2013) 1.55
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med (2014) 1.52
Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health (2005) 1.50
Dental visits to hospital emergency departments by adults receiving Medicaid: assessing their use. J Am Dent Assoc (2002) 1.49
Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant (2009) 1.46
Cigarette smoking, kidney function, and mortality after live donor kidney transplant. Am J Kidney Dis (2010) 1.45
Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. Urology (2011) 1.44
BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl (2002) 1.43
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. Am J Manag Care (2011) 1.39
Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant (2005) 1.37
Potential benefits and problems with computerized prescriber order entry: analysis of a voluntary medication error-reporting database. Am J Health Syst Pharm (2006) 1.29
Center effects in anemia management of dialysis patients. J Am Soc Nephrol (2007) 1.22
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Exploring donors' and recipients' attitudes about living donor kidney transplantation. Prog Transplant (2003) 1.22
An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol (2006) 1.21
Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology (2013) 1.18
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med (2013) 1.17
Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv Res (2007) 1.16
Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Med Care Res Rev (2006) 1.13
Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther (2003) 1.12
Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) (2011) 1.12
Barriers to self-management of diabetes: a qualitative study among low-income minority diabetics. Ethn Dis (2011) 1.12
Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc (2009) 1.11
Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clin Trials (2013) 1.11
Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med (2010) 1.10
A study of renal outcomes in African American living kidney donors. Transplantation (2009) 1.09
Disparity implications of Medicare eligibility criteria for medication therapy management services. Health Serv Res (2010) 1.09
Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2012) 1.09
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis (2013) 1.08
Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J (2006) 1.08
Increasing the use of arteriovenous fistula in hemodialysis: economic benefits and economic barriers. Clin J Am Soc Nephrol (2007) 1.07
Preemptive renal transplantation: why not? Am J Transplant (2003) 1.07
The development of direct-to-consumer prescription drug advertising regulation. Food Drug Law J (2002) 1.06
Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care (2008) 1.06
Impact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost. Am J Manag Care (2004) 1.06
Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol (2010) 1.05
Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc (2009) 1.05
Burden of COPD, asthma, and concomitant COPD and asthma among adults: racial disparities in a medicaid population. Chest (2009) 1.03
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Med Res Methodol (2012) 1.03
Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation. Med Care (2009) 1.02
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis (2011) 1.02
Stakeholder engagement in patient-centered outcomes research: high-touch or high-tech? Expert Rev Pharmacoecon Outcomes Res (2014) 1.01
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail (2009) 1.00
Medication access through patient assistance programs. Am J Health Syst Pharm (2006) 1.00
Reasons for discharges against medical advice: a qualitative study. Qual Saf Health Care (2010) 0.99
Drug therapy persistence and stroke recurrence. Am J Manag Care (2006) 0.98
Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting. Appl Health Econ Health Policy (2014) 0.98
The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care (2009) 0.98
Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol (2013) 0.97
Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. J Ren Nutr (2012) 0.97
Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int (2004) 0.97
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
The evolving role of mTOR inhibition in transplantation tolerance. J Am Soc Nephrol (2011) 0.96
Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin (2010) 0.96
The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation (2010) 0.96
Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Curr Med Res Opin (2009) 0.96
White paper: value of specialty certification in pharmacy. J Am Pharm Assoc (2003) (2004) 0.95
Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med (2008) 0.95
Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care (2002) 0.95
Exploring the relationship between Alzheimer's disease severity and longitudinal costs. Value Health (2012) 0.94
Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverage. Health Serv Res (2008) 0.94
Haemodialysis patients' readiness to pursue live donor kidney transplantation. Nephrol Dial Transplant (2009) 0.93
Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare. Med Care (2015) 0.93
The metabolic syndrome: a call to action. Coron Artery Dis (2006) 0.93
Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther (2007) 0.93
The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): a randomized trial of the effect of education on improving blood pressure control in a largely African American population. J Clin Hypertens (Greenwich) (2011) 0.93
Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med (2010) 0.93
The positive predictive value of a hyperkalemia diagnosis in automated health care data. Pharmacoepidemiol Drug Saf (2010) 0.92